-
WCLC 2024 | Dr. Kenneth O’Byrne：Spatial Metabolic Mapping Accelerates Biomarker Development for Predicting ICI Therapy Responses
Immune checkpoint inhibitors (ICIs) have brought new hope to the treatment of non-small cell lung cancer (NSCLC). However, their effectiveness is limited to only a subset of patients. Current biomarkers, such as tumor mutational burden (TMB) and PD-L1, show limited predictive power. According to Dr. Kenneth O’Byrne’s report(Icon Cancer Centre Greenslope) at the 2024 World…
-
Congratulations！iLIVER Executive Editor Tian Yang Awarded “National Distinguished Youth Scholar”
The review results of the 2024 National Natural Science Foundation of China (NSFC) centralized application period projects were recently announced. Dr. Tian Yang from the Third Affiliated Hospital of Naval Medical University was awarded the National Distinguished Youth Science Fund Project.
-
Dr. Meiqi Shi’s In-Depth Discussion: Key Topics in Lung Cancer Immunotherapy | CSCO Lung Cancer Standardized Treatment Workshop
Since the FDA approval of the first lung cancer immunotherapy regimen in 2015 based on the CheckMate-017 and 057 studies, lung cancer immunotherapy has evolved significantly over the past decade, becoming the first-line standard of care for patients with driver mutation-negative non-small cell lung cancer (NSCLC). However, as evidence accumulates and clinical experience grows, some…
-
ESMO 2024 | Dr. Tian Yang on New Liver Cancer Screening Method using Digital PCR Detection of Circulating Tumor DNA Methylation Markers
Liver cancer, often referred to as the “silent killer,” is frequently diagnosed at an advanced stage. Current screening methods such as alpha-fetoprotein (AFP) testing and ultrasound lack sufficient sensitivity and specificity. Therefore, there is an urgent need for more efficient, accurate, and cost-effective screening tools. At the 2024 ESMO conference, former President of the Korean…
-
ILCA 2024 | Dr. Zilin Cui: Milan Criteria vs. Ontario Criteria—A UNOS Analysis
In clinical practice, several criteria are available for evaluating liver transplant candidates, such as the Milan Criteria, UCSF Criteria in the U.S., Ontario Criteria in Canada, and domestic standards like the Fudan Criteria and Hangzhou Criteria in China. Among these, the Milan Criteria are the most widely adopted. However, differences in survival outcomes based on…
-
Dr. Arnaud Pigneux: Sharing the Innovative Achievements of AML Treatment by the French Innovative Leukemia Organization (FILO)
Recently, the 11th Sino-French Hematology Academic Conference successfully took place in Tianjin, China, attracting hundreds of top authorities and scholars in the field of hematology from both domestic and international circles. During the conference, “Hematology Frontier” specially invited Dr. Arnaud Pigneux from Haut-Leveque Hospital, University of Bordeaux, to discuss the innovative practice achievements of the…
-
ESMO China Voice: Personalized ctDNA Methylation for Monitoring MRD Post-Liver Cancer Resection by Fan Jia, Jian Zhou & Xinrong Yang’s Team
The study design encompasses recruiting around 200 patients with hepatocellular carcinoma (HCC) who have undergone radical surgery, with a two-year follow-up. Samples of cancer tissue, adjacent tissue, and blood are…
-
Exclusive Interview with Dr. Xiaobing Chen: New Strategies for Early Screening and Immunotherapy in Esophageal Cancer
At the 2024 Chinese Anti-Cancer Association (CACA) Integration of Esophageal Cancer Academic Conference, Oncology Frontier invited Dr. Xiaobing Chen, Secondary Professor/Chief Physician at the Department of Internal Medicine at Henan Cancer Hospital and Chair of the CACA Esophageal Tumor Integrated Rehabilitation Committee, to provide an in-depth analysis of early signs of esophageal cancer, screening methods,…
Connecting Medical Expertise through Media